| Cash Flow | 2025-06-30 |
|---|---|
| Net loss | -8,484,763 |
| Stock-based compensation | 1,446,824 |
| Amortization of loan commitment fee | 382,014 |
| Grant receivable | -73,218 |
| Prepaid expenses | 152,351 |
| Accounts payable | 67,749 |
| Accrued expenses | 159,356 |
| Net cash used in operating activities | -6,349,687 |
| Proceeds from issuance of common stock | 15,000,000 |
| Payment of financing/offering costs | -116,664 |
| Net cash provided by (used in) financing activities | 14,883,336 |
| Net increase (decrease) in cash and cash equivalents | 8,533,649 |
| Cash and cash equivalents at beginning of period | 3,094,200 |
| Cash and cash equivalents at end of period | 11,627,849 |
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)